|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Enrich C, Rentero C and Grewal T: Annexin
A6 in the liver: From the endocytic compartment to cellular
physiology. Biochim Biophys Acta Mol Cell Res. 1864:933–946. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sugimoto MA, Vago JP, Teixeira MM and
Sousa LP: Annexin A1 and the resolution of inflammation: Modulation
of neutrophil recruitment, apoptosis, and clearance. J Immunol Res.
2016:82392582016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rand JH, Wu XX, Quinn AS and Taatjes DJ:
Resistance to annexin A5 anticoagulant activity: A thrombogenic
mechanism for the antiphospholipid syndrome. Lupus. 17:922–930.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gerke V, Creutz CE and Moss SE: Annexins:
linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell
Biol. 6:449–461. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mussunoor S and Murray GI: The role of
annexins in tumour development and progression. J Pathol.
216:131–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ydy LR, do Espirito Santo GF, de Menezes
I, Martins MS, Ignotti E and Damazo AS: Study of the annexin A1 and
its associations with carcinoembryonic antigen and mismatch repair
proteins in colorectal cancer. J Gastrointest Cancer. 47:61–68.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Biaoxue R, Xiling J, Shuanying Y, Wei Z,
Xiguang C, Jinsui W and Min Z: Upregulation of Hsp90-beta and
annexin A1 correlates with poor survival and lymphatic metastasis
in lung cancer patients. J Exp Clin Cancer Res. 31:702012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao Y, Chen Y, Xu D, Wang J and Yu G:
Differential expression of ANXA1 in benign human gastrointestinal
tissues and cancers. BMC Cancer. 14:5202014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin Y, Lin G, Fang W, Zhu H and Chu K:
Increased expression of annexin A1 predicts poor prognosis in human
hepatocellular carcinoma and enhances cell malignant phenotype. Med
Oncol. 31:3272014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ibrahim MM, Sun MZ, Huang Y, Jun M, Jin Y,
Yue D, Jiasheng W, Zhang J, Qazi AS, Sagoe K and Tang J:
Down-regulation of ANXA7 decreases metastatic potential of human
hepatocellular carcinoma cells in vitro. Biomed Pharmacother.
67:285–291. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu SH, Lin CY, Peng SY, Jeng YM, Pan HW,
Lai PL, Liu CL and Hsu HC: Down-regulation of annexin A10 in
hepatocellular carcinoma is associated with vascular invasion,
early recurrence, and poor prognosis in synergy with p53 mutation.
Am J Pathol. 160:1831–1837. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu YY, Ge C, Tian H, Jiang JY, Zhao FY,
Li H, Chen TY, Yao M and Li JJ: The transcription factor Ikaros
inhibits cell proliferation by downregulating ANXA4 expression in
hepatocellular carcinoma. Am J Cancer Res. 7:1285–1297.
2017.PubMed/NCBI
|
|
16
|
Meier EM, Rein-Fischboeck L, Pohl R,
Wanninger J, Hoy AJ, Grewal T, Eisinger K, Krautbauer S, Liebisch
G, Weiss TS and Buechler C: Annexin A6 protein is downregulated in
human hepatocellular carcinoma. Mol Cell Biochem. 418:81–90. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mohammad HS, Kurokohchi K, Yoneyama H,
Tokuda M, Morishita A, Jian G, Shi L, Murota M, Tani J, Kato K, et
al: Annexin A2 expression and phosphorylation are up-regulated in
hepatocellular carcinoma. Int J Oncol. 33:1157–1163.
2008.PubMed/NCBI
|
|
18
|
Pan QZ, Pan K, Weng DS, Zhao JJ, Zhang XF,
Wang DD, Lv L, Jiang SS, Zheng HX and Xia JC: Annexin A3 promotes
tumorigenesis and resistance to chemotherapy in hepatocellular
carcinoma. Mol Carcinog. 54:598–607. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cancer Genome Atlas Research Network.
Electronic address, . simplewheeler@bcm.edu; Cancer
Genome Atlas Research Network: Comprehensive and integrative
genomic characterization of hepatocellular carcinoma. Cell.
169:1327–1341.e23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mas VR, Maluf DG, Archer KJ, Yanek K, Kong
X, Kulik L, Freise CE, Olthoff KM, Ghobrial RM, McIver P and Fisher
R: Genes involved in viral carcinogenesis and tumor initiation in
hepatitis C virus-induced hepatocellular carcinoma. Mol Med.
15:85–94. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roessler S, Jia HL, Budhu A, Forgues M, Ye
QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX and Wang XW: A
unique metastasis gene signature enables prediction of tumor
relapse in early-stage hepatocellular carcinoma patients. Cancer
Res. 70:10202–10212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wurmbach E, Chen YB, Khitrov G, Zhang W,
Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, et
al: Genome-wide molecular profiles of HCV-induced dysplasia and
hepatocellular carcinoma. Hepatology. 45:938–947. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sheikh MH and Solito E: Annexin A1:
Uncovering the many talents of an old protein. Int J Mol Sci.
19(pii): E10452018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
D'Acquisto F, Piras G and Rattazzi L:
Pro-inflammatory and pathogenic properties of Annexin-A1: The whole
is greater than the sum of its parts. Biochem Pharmacol.
85:1213–1218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Locatelli I, Sutti S, Jindal A, Vacchiano
M, Bozzola C, Reutelingsperger C, Kusters D, Bena S, Parola M,
Paternostro C, et al: Endogenous annexin A1 is a novel protective
determinant in nonalcoholic steatohepatitis in mice. Hepatology.
60:531–544. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moraes LA, Kar S, Foo SL, Gu T, Toh YQ,
Ampomah PB, Sachaphibulkij K, Yap G, Zharkova O, Lukman HM, et al:
Annexin-A1 enhances breast cancer growth and migration by promoting
alternative macrophage polarization in the tumour microenvironment.
Sci Rep. 7:179252017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
de Graauw M, van Miltenburg MH, Schmidt
MK, Pont C, Lalai R, Kartopawiro J, Pardali E, Le Dévédec SE, Smit
VT, van der Wal A, et al: Annexin A1 regulates TGF-beta signaling
and promotes metastasis formation of basal-like breast cancer
cells. Proc Natl Acad Sci USA. 107:6340–6345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suo A, Zhang M, Yao Y, Zhang L, Huang C,
Nan K and Zhang W: Proteome analysis of the effects of sorafenib on
human hepatocellular carcinoma cell line HepG2. Med Oncol.
29:1827–1836. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hongsrichan N, Rucksaken R, Chamgramol Y,
Pinlaor P, Techasen A, Yongvanit P, Khuntikeo N, Pairojkul C and
Pinlaor S: Annexin A1: A new immunohistological marker of
cholangiocarcinoma. World J Gastroenterol. 19:2456–2465. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xue LY, Teng LH, Zou SM, Ren LQ, Zheng S,
Luo W, Bi R and Lü N: Expression of annexin I in different
histological types of carcinomas. Zhonghua Zhong Liu Za Zhi.
29:444–448. 2007.(In Chinese). PubMed/NCBI
|
|
33
|
Luo CH, Liu QQ, Zhang PF, Li MY, Chen ZC
and Liu YF: Prognostic significance of annexin II expression in
non-small cell lung cancer. Clin Transl Oncol. 15:938–946. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang T, Yuan J, Zhang J, Tian R, Ji W,
Zhou Y, Yang Y, Song W, Zhang F and Niu R: Anxa2 binds to STAT3 and
promotes epithelial to mesenchymal transition in breast cancer
cells. Oncotarget. 6:30975–30992. 2015.PubMed/NCBI
|
|
35
|
Han Y, Ye J, Dong Y, Xu Z and Du Q:
Expression and significance of annexin A2 in patients with gastric
adenocarcinoma and the association with E-cadherin. Exp Ther Med.
10:549–554. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang YK, Liu H, Wang XZ and Zhu S:
Annexin A2 and CD105 expression in pancreatic ductal adenocarcinoma
is associated with tumor recurrence and prognosis. Asian Pac J
Cancer Prev. 15:9921–9926. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xiu D, Liu L, Qiao F, Yang H, Cui L and
Liu G: Annexin A2 coordinates STAT3 to regulate the invasion and
migration of colorectal cancer cells in vitro. Gastroenterol Res
Pract. 2016:35214532016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang H, Yao M, Wu W, Qiu L, Sai W, Yang
J, Zheng W, Huang J and Yao D: Up-regulation of annexin A2
expression predicates advanced clinicopathological features and
poor prognosis in hepatocellular carcinoma. Tumour Biol.
36:9373–9383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kling T, Ferrarese R, Ó hAilín D,
Johansson P, Heiland DH, Dai F, Vasilikos I, Weyerbrock A, Jörnsten
R, Carro MS and Nelander S: Integrative modeling reveals annexin
A2-mediated epigenetic control of mesenchymal glioblastoma.
EBioMedicine. 12:72–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Luo S, Xie C, Wu P, He J, Tang Y, Xu J and
Zhao S: Annexin A2 is an independent prognostic biomarker for
evaluating the malignant progression of laryngeal cancer. Exp Ther
Med. 14:6113–6118. 2017.PubMed/NCBI
|
|
41
|
Liu Y, Myrvang HK and Dekker LV: Annexin
A2 complexes with S100 proteins: Structure, function and
pharmacological manipulation. Br J Pharmacol. 172:1664–1676. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang CY, Chen CL, Tseng YL, Fang YT, Lin
YS, Su WC, Chen CC, Chang KC, Wang YC and Lin CF: Annexin A2
silencing induces G2 arrest of non-small cell lung cancer cells
through p53-dependent and -independent mechanisms. J Biol Chem.
287:32512–32524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jung H, Kim JS, Kim WK, Oh KJ, Kim JM, Lee
HJ, Han BS, Kim DS, Seo YS, Lee SC, et al: Intracellular annexin A2
regulates NF-κB signaling by binding to the p50 subunit:
Implications for gemcitabine resistance in pancreatic cancer. Cell
Death Dis. 6:e16062015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang HJ, Yao DF, Yao M, Huang H, Wu W,
Yan MJ, Yan XD and Chen J: Expression characteristics and
diagnostic value of annexin A2 in hepatocellular carcinoma. World J
Gastroenterol. 18:5897–5904. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang W, Zhao P, Xu XL, Cai L, Song ZS,
Cao DY, Tao KS, Zhou WP, Chen ZN and Dou KF: Annexin A2 promotes
the migration and invasion of human hepatocellular carcinoma cells
in vitro by regulating the shedding of CD147-harboring
microvesicles from tumor cells. PLoS One. 8:e672682013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
El-Abd N, Fawzy A, Elbaz T and Hamdy S:
Evaluation of annexin A2 and as potential biomarkers for
hepatocellular carcinoma. Tumour Biol. 37:211–216. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Du R, Liu B, Zhou L, Wang D, He X, Xu X,
Zhang L, Niu C and Liu S: Downregulation of annexin A3 inhibits
tumor metastasis and decreases drug resistance in breast cancer.
Cell Death Dis. 9:1262018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang K and Li J: Overexpression of ANXA3
is an independent prognostic indicator in gastric cancer and its
depletion suppresses cell proliferation and tumor growth.
Oncotarget. 7:86972–86984. 2016.PubMed/NCBI
|
|
49
|
Köllermann J, Schlomm T, Bang H, Schwall
GP, von Eichel-Streiber C, Simon R, Schostak M, Huland H, Berg W,
Sauter G, et al: Expression and prognostic relevance of annexin A3
in prostate cancer. Eur Urol. 54:1314–1323. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pan QZ, Pan K, Wang QJ, Weng DS, Zhao JJ,
Zheng HX, Zhang XF, Jiang SS, Lv L, Tang Y, et al: Annexin A3 as a
potential target for immunotherapy of liver cancer stem-like cells.
Stem Cells. 33:354–366. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tong M, Fung TM, Luk ST, Ng KY, Lee TK,
Lin CH, Yam JW, Chan KW, Ng F, Zheng BJ, et al: ANXA3/JNK signaling
promotes self-renewal and tumor growth, and its blockade provides a
therapeutic target for hepatocellular carcinoma. Stem Cell Reports.
5:45–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ma XL, Jiang M, Zhao Y, Wang BL, Shen MN,
Zhou Y, Zhang CY, Sun YF, Chen JW, Hu B, et al: Application of
serum annexin A3 in diagnosis, outcome prediction and therapeutic
response evaluation for patients with hepatocellular carcinoma. Ann
Surg Oncol. 25:1686–1694. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dreier R, Schmid KW, Gerke V and Riehemann
K: Differential expression of annexins I, II and IV in human
tissues: An immunohistochemical study. Histochem Cell Biol.
110:137–148. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gaudio E, Paduano F, Ngankeu A, Ortuso F,
Lovat F, Pinton S, D'Agostino S, Zanesi N, Aqeilan RI, Campiglia P,
et al: A Fhit-mimetic peptide suppresses annexin A4-mediated
chemoresistance to paclitaxel in lung cancer cells. Oncotarget.
7:29927–29936. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Duncan R, Carpenter B, Main LC, Telfer C
and Murray GI: Characterisation and protein expression profiling of
annexins in colorectal cancer. Br J Cancer. 98:426–433. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Choi CH, Chung JY, Chung EJ, Sears JD, Lee
JW, Bae DS and Hewitt SM: Prognostic significance of annexin A2 and
annexin A4 expression in patients with cervical cancer. BMC Cancer.
16:4482016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yao HS, Sun C, Li XX, Wang Y, Jin KZ,
Zhang XP and Hu ZQ: Annexin A4-nuclear factor-kappaB feedback
circuit regulates cell malignant behavior and tumor growth in
gallbladder cancer. Sci Rep. 6:310562016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chen W, Chen L, Cai Z, Liang D, Zhao B,
Zeng Y, Liu X and Liu J: Overexpression of annexin A4 indicates
poor prognosis and promotes tumor metastasis of hepatocellular
carcinoma. Tumour Biol. 37:9343–9355. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Peng B, Guo C, Guan H, Liu S and Sun MZ:
Annexin A5 as a potential marker in tumors. Clin Chim Acta.
427:42–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Guo WX, Man XB, Yuan HX, Shi J, Xue J, Wu
MC and Cheng SQ: Proteomic analysis on portal vein tumor
thrombus-associated proteins for hepatocellular carcinoma. Zhonghua
Yi Xue Za Zhi. 87:2094–2097. 2007.(In Chinese). PubMed/NCBI
|
|
61
|
Sun X, Liu S, Wang J, Wei B, Guo C, Chen C
and Sun MZ: Annexin A5 regulates hepatocarcinoma malignancy via
CRKI/II-DOCK180-RAC1 integrin and MEK-ERK pathways. Cell Death Dis.
9:6372018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Srivastava M, Torosyan Y, Raffeld M,
Eidelman O, Pollard HB and Bubendorf L: ANXA7 expression represents
hormone-relevant tumor suppression in different cancers. Int J
Cancer. 121:2628–2636. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Du Y, Meng J, Huang Y, Wu J, Wang B,
Ibrahim MM and Tang J: Guanine nucleotide-binding protein subunit
beta-2-like 1, a new Annexin A7 interacting protein. Biochem
Biophys Res Commun. 445:58–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Song L, Mao J, Zhang J, Ibrahim MM, Li LH
and Tang JW: Annexin A7 and its binding protein galectin-3
influence mouse hepatocellular carcinoma cell line in vitro. Biomed
Pharmacother. 68:377–384. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Huang Y, Wang Q, Du Y, Bai L, Jin F, Zhang
J, Fan S, Wang H, Song L, Gao Y, et al: Inhibition of annexin A7
gene and protein induces the apotosis and decreases the invasion,
migration of the hepatocarcinoma cell line. Biomed Pharmacother.
68:819–824. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wang XY, Gao F, Sun YR, Bai LL, Ibrahim
MM, Wang B and Tang JW: In vivo and in vitro effect of
hepatocarcinoma lymph node metastasis by upregulation of Annexin A7
and relevant mechanisms. Tumour Biol. 37:911–924. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Morgan RO, Jenkins NA, Gilbert DJ,
Copeland NG, Balsara BR, Testa JR and Fernandez MP: Novel human and
mouse annexin A10 are linked to the genome duplications during
early chordate evolution. Genomics. 60:40–49. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kim J, Kim MA, Jee CD, Jung EJ and Kim WH:
Reduced expression and homozygous deletion of annexin A10 in
gastric carcinoma. Int J Cancer. 125:1842–1850. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
van der Heijden AG, Mengual L, Lozano JJ,
Ingelmo-Torres M, Ribal MJ, Fernández PL, Oosterwijk E, Schalken
JA, Alcaraz A and Witjes JA: A five-gene expression signature to
predict progression in T1G3 bladder cancer. Eur J Cancer.
64:127–136. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhu J, Wu J, Pei X, Tan Z, Shi J and
Lubman DM: Annexin A10 is a candidate marker associated with the
progression of pancreatic precursor lesions to adenocarcinoma. PLoS
One. 12:e01750392017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Liu X, Peng X, Hu Z, Zhao Q, He J, Li J
and Zhong X: Effects of over-expression of ANXA10 gene on
proliferation and apoptosis of hepatocellular carcinoma cell line
HepG2. J Huazhong Univ Sci Technolog Med Sci. 32:669–674. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Li Y, Xu A, Jia S and Huang J: Recent
advances in the molecular mechanism of sex disparity in
hepatocellular carcinoma. Oncol Lett. 17:4222–4228. 2019.PubMed/NCBI
|
|
73
|
Liu C, Ren YF, Dong J, Ke MY, Ma F, Monga
SPS, Wu R, Lv Y and Zhang XF: Activation of SRY accounts for
male-specific hepatocarcinogenesis: Implication in gender disparity
of hepatocellular carcinoma. Cancer Lett. 410:20–31. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zheng B, Zhu YJ, Wang HY and Chen L:
Gender disparity in hepatocellular carcinoma (HCC): Multiple
underlying mechanisms. Sci China Life Sci. 60:575–584. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Naugler WE, Sakurai T, Kim S, Maeda S, Kim
K, Elsharkawy AM and Karin M: Gender disparity in liver cancer due
to sex differences in MyD88-dependent IL-6 production. Science.
317:121–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kanda T, Takahashi K, Nakamura M, Nakamoto
S, Wu S, Haga Y, Sasaki R, Jiang X and Yokosuka O: Androgen
receptor could be a potential therapeutic target in patients with
advanced hepatocellular carcinoma. Cancers (Basel). 9:pii432017.
View Article : Google Scholar
|
|
77
|
Yeh SH and Chen PJ: Gender disparity of
hepatocellular carcinoma: The roles of sex hormones. Oncology. 78
(Suppl 1):S172–S179. 2010. View Article : Google Scholar
|
|
78
|
Torosyan Y, Simakova O, Naga S, Mezhevaya
K, Leighton X, Diaz J, Huang W, Pollard H and Srivastava M:
Annexin-A7 protects normal prostate cells and induces distinct
patterns of RB-associated cytotoxicity in androgen-sensitive and
-resistant prostate cancer cells. Int J Cancer. 125:2528–2539.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Grewal T, Wason SJ, Enrich C and Rentero
C: Annexins-insights from knockout mice. Biol Chem. 397:1031–1053.
2016. View Article : Google Scholar : PubMed/NCBI
|
